Showing results (461-470 of 521) with videos related to
Sort By:
Pageof 53
Trials|June 19, 2019
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapyWesley de Jong, Joeri Aerts, Sabine Allard, et al.European Journal of Haematology|December 1, 2011
Prognostic value of PINI index in patients with multiple myelomaSophie Dupire, Mathieu Wemeau, Houria Debarri, et al.Melanoma Research|February 15, 2011
Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative casesSofie Wilgenhof, Lauranne Pierret, Jurgen Corthals, et al.Molecular Therapy. Nucleic Acids|November 21, 2013
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In VivoDaphné Benteyn, Sébastien Anguille, Sandra Van Lint, et al.Vaccine|June 10, 2008
Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and NefSabine D Allard, Katrien Pletinckx, Karine Breckpot, et al.Gastroenterology|January 24, 2007
Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndromeMichael Camilleri, Christopher N Andrews, Adil E Bharucha, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanomaSofie Wilgenhof, An M T Van Nuffel, Jurgen Corthals, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survivalElke De Bruyne, Tomas Jan Bos, Kewal Asosingh, et al.Cancer Immunology Research|December 15, 2015
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic CellsSandra Van Lint, Dries Renmans, Katrijn Broos, et al.Cancer Cell|November 11, 2022
Challenges in neoantigen-directed therapeuticsLien Lybaert, Steve Lefever, Bruno Fant, et al.Pageof 53